Related Experiment Video
Updated: Jun 25, 2026
Platform for Quantitative Detection of Endometrial Immune Cells Based on Immunohistochemistry and Digital Image Analysis
Published on: October 13, 2023
A systematic review of immune checkpoint inhibitors in endometrial cancer
Na Zhu1,2, Chaihong Zhang3
1Clinical Trial Institution Office, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
Background:
Endometrial cancer represents one of the most prevalent gynecological malignancies. This study aims to systematically analyze the knowledge frameworks, key contributors, research hotspots, emerging trending topics, and future directions in the field of immune checkpoint inhibitors for endometrial cancer by applying bibliometric methodologies.
Methods:
A thorough and methodical search of the Web of Science Core Collection (WoSCC) database and the PubMed database was performed to identify publications related to immune checkpoint inhibitors in endometrial cancer from January 1, 2015, to December 31, 2024. Furthermore, bibliometric analysis and knowledge map visualization were conducted utilizing VOSviewer, Biblioshiny, and CiteSpace.
Results:
For the WoSCC database, this research involved an analysis of 829 publications disseminated across 296 journals, authored by 5,145 researchers affiliated with 1,535 institutions from 63 different countries. For the PubMed database, this research involved an analysis of 279 publications disseminated across 120 journals, authored by 1,611 researchers affiliated with 974 institutions from 46 different countries. The leading three contributors to publication volume were United States, China, and Italy. Importantly, the highest level of international collaboration has been recorded between United States and England. Gynecologic Oncology, Cancers, Frontiers in Immunology, Frontiers in Oncology, and the Journal of Clinical Oncology are acknowledged as the five most influential journals regarding immune checkpoint inhibitors for endometrial cancer. Makker Vicky emerged as the most influential author, while Memorial Sloan Kettering Cancer Center was identified as the most influential institution. Current research hotspots regarding immune checkpoint inhibitors in the treatment of endometrial cancer include microsatellite instability, mismatch repair deficiency, PD-1, PD-L1, chemotherapy, pembrolizumab, lenvatinib, and dostarlimab. Additionally, emerging trending topics in this field encompass pembrolizumab, lenvatinib, dostarlimab, immune checkpoint inhibitors, and mismatch repair deficiency.
Conclusion:
An in-depth exploration of the molecular mechanisms of immune checkpoint inhibitors for endometrial cancer is crucial for overcoming the current clinical challenges associated with immunotherapy. This study systematically analyzes the current state of research in this field, focusing on research hotspots, emerging trends, and future development directions. Additionally, it comprehensively evaluates the most influential literature, core journals, authoritative scholars, leading research institutions, and major contributing countries in this field.
Insights
This bibliometric study analyzes immune checkpoint inhibitors for endometrial cancer, identifying key research trends and influential contributors. Findings highlight microsatellite instability and PD-1/PD-L1 as current hotspots for advancing immunotherapy.
Area of Science:
- Gynecologic Oncology
- Immunotherapy
- Bibliometrics
Background:
- Endometrial cancer is a significant gynecological malignancy.
- Immune checkpoint inhibitors (ICIs) are a key therapeutic strategy.
- Understanding the research landscape of ICIs in endometrial cancer is crucial.
Purpose of the Study:
- To systematically analyze knowledge frameworks, contributors, hotspots, and trends in endometrial cancer ICI research.
- To identify influential publications, authors, institutions, and countries.
- To map the evolution and future directions of this research field.
Main Methods:
- Bibliometric analysis of publications from Web of Science Core Collection and PubMed (2015-2024).
- Utilized VOSviewer, Biblioshiny, and CiteSpace for data analysis and visualization.
- Analyzed publication volume, citations, collaboration networks, and keyword frequencies.
Main Results:
- Analysis of 829 (WoSCC) and 279 (PubMed) publications.
- Top contributing countries: United States, China, Italy; highest collaboration: US and England.
- Key journals: Gynecologic Oncology, Cancers, Frontiers in Immunology.
- Influential author: Makker Vicky; institution: Memorial Sloan Kettering Cancer Center.
- Research hotspots: microsatellite instability, mismatch repair deficiency, PD-1, PD-L1, pembrolizumab, lenvatinib, dostarlimab.
Conclusions:
- In-depth exploration of molecular mechanisms is vital for overcoming immunotherapy challenges.
- This study provides a comprehensive overview of current research, hotspots, and trends.
- Identifies key players and influential works to guide future research in endometrial cancer immunotherapy.
